CAR T cell therapy, a cancer treatment that reprograms a patient's own immune cells to hunt and destroy specific targets, is now being tested in hundreds of clinical trials for autoimmune diseases including multiple sclerosis, lupus, Graves' disease, and vasculitis.
Jan Janisch-Hanzlik, 49, became the first enrolled patient in a CAR T trial at the University of Nebraska Medical Center in Omaha after standard MS medications failed her. She had already left her nursing role, feared carrying her grandchildren due to frequent falls, and bought a larger house to accommodate a wheelchair she expected to need permanently. She called the clinic every other month until they were ready for her.
The mechanism matters: CAR T does not just suppress autoimmune activity, it aims to eliminate the cells causing it and reset the immune system to a pre-disease state. Whether that durability holds in autoimmune conditions the way it has in blood cancers is the open question the trials are designed to answer. The full article details the biological reasoning behind why that reset might actually work.
[READ ORIGINAL →]